Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PureTech Health ( (GB:PRTC) ) has issued an update.
PureTech Health’s Founded Entity, Seaport Therapeutics, presented new data from a Phase 1 study of SPT-300, an oral prodrug of allopregnanolone, at the ACNP Annual Meeting 2024. The study showed SPT-300 was well-tolerated with promising pharmacodynamic activity, suggesting its suitability for chronic dosing in a planned Phase 2b study targeting major depressive disorder, potentially positioning it as a rapidly acting antidepressant and anxiolytic agent.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company that focuses on developing new classes of medicine to address devastating diseases. It boasts a broad pipeline of 29 therapeutic candidates, including three that have received FDA approval, developed both internally and through its Founded Entities.
YTD Price Performance: -13.08%
Average Trading Volume: 687,579
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £404.1M
Find detailed analytics on PRTC stock on TipRanks’ Stock Analysis page.
